Skip to main content
main-content

05-06-2021 | ASCO 2021 | Conference coverage | Video

Sotorasib continues to show potential in KRAS-mutant NSCLC

Ferdinandos Skoulidis presents an update from the CodeBreaK 100 trial of sotorasib in previously treated patients with non-small-cell lung cancer and KRAS G12C mutations, focusing on overall survival data and a subgroup analysis by co-mutations (3:58).

Read transcript

Image Credits